{"filing":{"accession_number":"0001171843-26-004747","cik":"0001828253","ticker":"EVAX","company_name":"Evaxion A/S","form":"6-K","filing_date":"2026-07-17","report_date":null,"primary_document":"f6k_071726.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828253/000117184326004747/f6k_071726.htm"},"events":[{"id":18578,"run_id":16702,"accession_number":"0001171843-26-004747","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"This press release announces Evaxion's presentation of three-year clinical efficacy data for its lead cancer vaccine candidate EVX-01 at the ESMO Congress 2026. The disclosure highlights positive trial results (75% ORR, 92% durability at two years, and new stand-alone therapy data) that are material to investors assessing the company's clinical progress and commercial prospects. While not a discrete event like an approval or M\u0026A transaction, the announcement of significant clinical milestone data from an ongoing phase 2 trial is a material operational/clinical development event that would affect a reasonable investor's assessment of the registrant's pipeline and competitive position.","company_name":"Evaxion A/S","ticker":"EVAX","filing_date":"2026-07-17","form":"6-K","submitted_at":null,"items":[{"id":17426,"accession_number":"0001171843-26-004747","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces Evaxion's presentation of three-year clinical efficacy data for its lead cancer vaccine candidate EVX-01 at the ESMO Congress 2026. The disclosure highlights positive trial results (75% ORR, 92% durability at two years, and new stand-alone therapy data) that are material to investors assessing the company's clinical progress and commercial prospects. While not a discrete event like an approval or M\u0026A transaction, the announcement of significant clinical milestone data from an ongoing phase 2 trial is a material operational/clinical development event that would affect a reasonable investor's assessment of the registrant's pipeline and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-17T11:31:49.499289+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17426,"accession_number":"0001171843-26-004747","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This press release announces Evaxion's presentation of three-year clinical efficacy data for its lead cancer vaccine candidate EVX-01 at the ESMO Congress 2026. The disclosure highlights positive trial results (75% ORR, 92% durability at two years, and new stand-alone therapy data) that are material to investors assessing the company's clinical progress and commercial prospects. While not a discrete event like an approval or M\u0026A transaction, the announcement of significant clinical milestone data from an ongoing phase 2 trial is a material operational/clinical development event that would affect a reasonable investor's assessment of the registrant's pipeline and competitive position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-17T11:31:49.499289+00:00","company_name":"Evaxion A/S","ticker":"EVAX","filing_date":"2026-07-17"}]}